Sanofi to Acquire Blueprint Medicines for up to $9.5 billion

Rare Daily Staff

Sanofi said it will acquire Blueprint Medicines for up to $9.5 billion, a move that will expand its portfolio in rare immunological diseases.

The acquisition will give Sanofi the rare immunology disease medicine Ayvakit/Ayvakyt, which is approved in the United States and European Union, as well as a promising advanced and early-stage immunology pipeline. Blueprint’s presence among allergists, dermatologists, and immunologists is also expected to enhance Sanofi’s growing immunology portfolio.

Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis, a rare immunological disease characterized by the accumulation and activation of aberrant mast cells in the bone marrow, skin, gastrointestinal tract, and other organs. The acquisition will also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology.

Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders will also receive one non-tradeable contingent value right (CVR), which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis.

“The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world’s leading immunology company,” said Paul Hudson, CEO of Sanofi. “This acquisition is fully aligned with our strategic intent to strengthen our existing therapeutic areas, bring relevant and differentiated medicines to patients, and secure attractive returns for our shareholders.”

Photo: Paul Hudson, CEO of Sanofi